Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapeutics V > Erdman Vancomycin and Other Agents Learning Objectives > Flashcards

Erdman Vancomycin and Other Agents Learning Objectives Flashcards

1
Q

Vanc MOA

A

Glycopeptide that inhibits sysnthesis of bacterial cell wall by blocking glycopeptide polymerization; inhibits synthesis and assembly during the second stage by binding to D-Ala-D-Ala portion = prevents cross-linking and further elongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Synercid MOA

A

Individually bind on the 50S ribosomal subunit to inhibit early and late stages of bacterial protein synthesis = bacteriostatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Oxazolidinones MOA

A

Bind to 50S ribosomal subunit near the surface interface of the 30S subunit = inhibits 70S initiation complex formation = inhibits protein synthesis = bacteriostatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Daptomycin MOA

A

Inserts lipophilic tail into cell wall to form a transmembrane channel = leakage of cellular contents and rapid depolarization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lipoglycopeptides MOA

A

Binds to D-Ala-D-Ala terminus = interferes with polymerization

Oritavancin and telavancin bind to membranes and insert lipophilic tail = cellular leakage of contents and rapid depolarization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Vanc MOR

A

VRE, VRSA –> modification of D-Ala-D-Ala to D-Ala-D-lactate via van gene

VISA: thickening of peptidoglycan layer of cell wall

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Synercid MOR

A

Alteration of ribosomal binding site via erm gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Oxazolidinones MOR

A

Alteration of the ribosomal subunit target site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Daptomycin MOR

A

Very rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Lipoglycopeptides MOR

A

Modification to D-Ala-D-Lactate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Vanc spectrum of activity

A

Gram positive aerobic and anaerobic bacteria

PRSP, MSSA, MRSA, C. diff. (oral form okay for C. diff)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Synercid spectrum of activity

A

PRSP, VRE (only faecium), MSSA, MRSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Oxazolidinones spectrum of activity

A

PRSP, VRE, MSSA, MRSA, VISA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Daptomycin spectrum of activity

A

PRSP, VRE, MSSA, MRSA, VISA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Lipoglycopeptides spectrum of activity

A

VRE, MSSA, MRSA, VISA, VRSA (oritavancin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Vanc major pharmacokinetic characteristics

A

Widely distributed (including adipose tissue)

Variable CSF penetration

Half-life progressively increases as renal function decreases

Not removed by hemodialysis

17
Q

Synercid major pharmacokinetic characteristics

A

Significant PAE

Hepatic/biliary excretion = no renal adjustment needed

18
Q

Oxazolidinones major pharmacokinetic characteristics

A

PAE

Oral bioavailability

Readily distributed to well-perfused tissues

Both renal and non-renal elimination = no renal adjustment

19
Q

Daptomycin major pharmacokinetic characteristics

A

Concentration dependent

Highly protein bound and distributes well into tissues

Renal elimination = requires renal dose adjustment

20
Q

Lipoglycopeptides major pharmacokinetic characteristics

A

Concentration dependent activity

Well distributed

21
Q

Telavancin and dialysis

A

kidney elimination = renal adjustment required

22
Q

Dalbavancin and dialysis

A

very loooooooooong half-life

renal adjustment required

23
Q

Oritavancin and dialysis

A

no renal adjustment

24
Q

Vanc clinical uses

A

MRSA, PRSP, C. diff (oral)

25
Q

Synercid clinical uses

A

VRE (faecium)

26
Q

Oxazolidinones clinical uses

A

VRE, nosocomial pneumonia, MRSA

27
Q

Daptomycin clinical uses

A

iUsed where vancomycin/linezolid cannot be used

DO NOT USE FOR PNEUMONIA!!!

28
Q

Lipoglycopeptides clinical uses

A

Used where vancomycin, linezolid/tedizolid, and daptomycin cannot be used

29
Q

Vanc AE

A

Red man syndrome: infusion related NOT an allergic reaction

Nephrotoxicity (reversible), ototoxicity (irreversible)

30
Q

Synercid AE

A

Venous irritation

myalgias

arthralgias

31
Q

Oxazolidinones AE

A

GI

CNS

Thrombocytopenia

anemia

32
Q

Daptomycin AE

A

GI

injection site reactions

myopathy

acute eosinophilic pneumonia

33
Q

Lipoglycopeptides AE

A

Red man syndrome (infusion related)

Nephrotoxicity

***QTC prolongation

Taste disturbance

***Pregnancy category C

34
Q

Synercid major interactions

A

Cytochrome P450 3A4 inhibitor

  1. Statins
  2. Cyclosporine
  3. Tacrolimus
  4. Carbamazepine
35
Q

Oxazolidinones major interactions

A

Monoamine oxidase inhibitors

  1. Risk of serotonin syndrome if taking SSRI/SNRI
36
Q

Daptomycin major interactions

A

Statins –> increased myopathy

37
Q

Lipoglycopeptides major interactions

A

Telavancin/oritavancin = interfere with coagulation tests

Therapeutics V (17 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions